• 1
    Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 7196.
  • 2
    American Cancer Society. Cancer Facts and Figures 2006. Atlanta: American Cancer Society; 2006.
  • 3
    Paruchuri S, Broom O, Dib K, Sjölander A. The pro-inflammatory mediator leukotriene D4 induces phosphatidylinositol 3-kinase and Rac-dependent migration of intestinal epithelial cells. J Biol Chem 2005; 280: 1353844.
  • 4
    Samuelsson B. Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science 1983; 220: 56875.
  • 5
    Kanaoka Y, Boyce JA. Cysteinyl leukotrienes and their receptors: cellular distribution and function in immune and inflammatory responses. J Immunol 2004; 173: 150310.
  • 6
    Back M, Hansson GK. Leukotriene receptors in atherosclerosis. Ann Med 2006; 38: 493502.
  • 7
    Lynch KR, O'Neill GP, Liu Q, Im DS, Sawyer N, Metters KM, Coulombe N, Abramovitz M, Figueroa DJ, Zeng Z, Connolly BM, Bai C, et al. Characterization of the human cysteinyl leukotriene CysLT1 receptor. Nature 1999; 399: 78993.
  • 8
    Heise CE, O'Dowd BF, Figueroa DJ, Sawyer N, Nguyen T, Im DS, Stocco R, Bellefeuille JN, Abramovitz M, Cheng R, Williams DL, Jr, Zeng Z, et al. Characterization of the human cysteinyl leukotriene 2 receptor. J Biol Chem 2000; 275: 305316.
  • 9
    Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001; 357: 53945.
  • 10
    Ma XJ, Dahiya S, Richardson E, Erlander M, Sgroi DC. Gene expression profiling of the tumor microenvironment during breast cancer progression. Breast Cancer Res 2009; 11: R7.
  • 11
    Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature 2001; 411: 3759.
  • 12
    Öhd JF, Nielsen CK, Campbell J, Landberg G, Löfberg H, Sjölander A. Expression of the leukotriene D4 receptor CysLT1, COX-2, and other cell survival factors in colorectal adenocarcinomas. Gastroenterology 2003; 124: 5770.
  • 13
    Paruchuri S, Sjölander A. Leukotriene D4 mediates survival and proliferation via separate but parallel pathways in the human intestinal Epithelial cell line Int 407. J Biol Chem 2003; 278: 4557785.
  • 14
    Öhd JF, Wikström K, Sjölander A. Leukotrienes induce cell-survival signaling in intestinal epithelial cells. Gastroenterology 2000; 119: 100718.
  • 15
    Magnusson C, Ehrnström R, Olsen J, Sjölander A. An increased expression of cysteinyl leukotriene 2 receptor in colorectal adenocarcinomas correlates with high differentiation. Cancer Res 2007; 67: 91908.
  • 16
    Jiang Y, Borrelli LA, Kanaoka Y, Bacskai BJ, Boyce JA. CysLT2 receptors interact with CysLT1 receptors and down-modulate cysteinyl leukotriene dependent mitogenic responses of mast cells. Blood 2007; 110: 326370.
  • 17
    Platet N, Cathiard AM, Gleizes M, Garcia M. Estrogens and their receptors in breast cancer progression: a dual role in cancer proliferation and invasion. Crit Rev Oncol Hematol 2004; 51: 5567.
  • 18
    Konecny G, Pauletti G, Pegram M, Untch M, Dandekar S, Aguilar Z, Wilson C, Rong HM, Bauerfeind I, Felber M, Wang HJ, Beryt M, et al. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst 2003; 95: 14253.
  • 19
    Thurlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Rabaglio M, Smith I, Wardley A, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005; 353: 274757.
  • 20
    Cuzick J. Epidemiology of breast cancer—selected highlights. Breast 2003; 12: 40511.
  • 21
    Cuzick J. Aromatase inhibitors in prevention—data from the ATAC (arimidex, tamoxifen alone or in combination) trial and the design of IBIS-II (the second International Breast Cancer Intervention Study). Recent Results Cancer Res 2003; 163: 96103; discussion 264–6.
  • 22
    Helczynska K, Larsson AM, Holmquist Mengelbier L, Bridges E, Fredlund E, Borgquist S, Landberg G, Påhlman S, Jirström K. Hypoxia-inducible factor-2alpha correlates to distant recurrence and poor outcome in invasive breast cancer. Cancer Res 2008; 68: 921220.
  • 23
    Nielsen CK, Campbell JI, Öhd JF, Mörgelin M, Riesbeck K, Landberg G, Sjölander A. A novel localization of the G-protein-coupled CysLT1 receptor in the nucleus of colorectal adenocarcinoma cells. Cancer Res 2005; 65: 73242.
  • 24
    Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19: 40310.
  • 25
    Klemke RL, Leng J, Molander R, Brooks PC, Vuori K, Cheresh DA. CAS/Crk coupling serves as a “molecular switch” for induction of cell migration. J Cell Biol 1998; 140: 96172.
  • 26
    Goetzl EJ. Diverse pathways for nuclear signaling by G protein-coupled receptors and their ligands. FASEB J 2007; 21: 63842.
  • 27
    Liao JJ, Huang MC, Graler M, Huang Y, Qiu H, Goetzl EJ. Distinctive T cell-suppressive signals from nuclearized type 1 sphingosine 1-phosphate G protein-coupled receptors. J Biol Chem 2007; 282: 196472.
  • 28
    Gobeil F, Jr, Bernier SG, Vazquez-Tello A, Brault S, Beauchamp MH, Quiniou C, Marrache AM, Checchin D, Sennlaub F, Hou X, Nader M, Bkaily G, et al. Modulation of pro-inflammatory gene expression by nuclear lysophosphatidic acid receptor type-1. J Biol Chem 2003; 278: 3887583.
  • 29
    Jans DA, Xiao CY, Lam MH. Nuclear targeting signal recognition: a key control point in nuclear transport? Bioessays 2000; 66: 53244.
  • 30
    van Leeuwen FE, Benraadt J, Coebergh JW, Kiemeney LA, Gimbrere CH, Otter R, Schouten LJ, Damhuis RA, Bontenbal M, Diepenhorst FW, van den Belt-Dusebout AW, van Tinteren H. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 1994; 343: 44852.
  • 31
    Bergman L, Beelen ML, Gallee MP, Hollema H, Benraadt J, van Leeuwen FE. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of Liver and Endometrial cancer Risk following Tamoxifen. Lancet 2000; 356: 8817.
  • 32
    Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687717.
  • 33
    Rose C. Increasing protection after tamoxifen: insights from the extended adjuvant aromatase inhibitor trials. J Cancer Res Clin Oncol 2008; 134: 717.
  • 34
    Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S, Boyle P. Overview of the main outcomes in breast-cancer prevention trials. Lancet 2003; 361: 296300.
  • 35
    Magnusson C, Mezhybovska M, Lörinc E, Fernebro E, Nilbert M, Sjölander A. Low expression of CysLT1R and high expression of CysLT2R mediate good prognosis in colorectal cancer. Eur J Cancer 2010; 46: 82635.
  • 36
    Blackwell KL, Haroon ZA, Shan S, Saito W, Broadwater G, Greenberg CS, Dewhirst MW. Tamoxifen inhibits angiogenesis in estrogen receptor-negative animal models. Clin Cancer Res 2000; 6: 435964.
  • 37
    Obrero M, Yu DV, Shapiro DJ. Estrogen receptor-dependent and estrogen receptor-independent pathways for tamoxifen and 4-hydroxytamoxifen-induced programmed cell death. J Biol Chem 2002; 277: 45695703.
  • 38
    Leng Y, Gu ZP, Cao L. Apoptosis induced by droloxifene and c-myc, bax and bcl-2 mRNA expression in cultured luteal cells of rats. Eur J Pharmacol 2000; 409: 12331.
  • 39
    Gundimeda U, Chen ZH, Gopalakrishna R. Tamoxifen modulates protein kinase C via oxidative stress in estrogen receptor-negative breast cancer cells. J Biol Chem 1996; 271: 1350414.
  • 40
    Bracke ME, Charlier C, Bruyneel EA, Labit C, Mareel MM, Castronovo V. Tamoxifen restores the E-cadherin function in human breast cancer MCF-7/6 cells and suppresses their invasive phenotype. Cancer Res 1994; 54: 46079.